• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

    10/30/24 12:55:00 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors

    Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/

    Adam Herbst (Photo: Business Wire)

    Adam Herbst (Photo: Business Wire)

    In joining Sheppard Mullin's industry-leading Healthcare team, Herbst specializes in healthcare policy, Medicaid reform and corporate governance, with a strong focus on transforming healthcare systems to ensure equitable access and improved quality for diverse populations, including children, seniors and individuals with disabilities.

    As Deputy Commissioner for Aging and Long Term Care at the Department of Health, Herbst oversaw regulation for the state of New York's acute care, post-acute care, disability and long-term care industries. As an advisor to the Governor of New York, he led state and federal policy and fiscal initiatives, including the Governor's Master Plan for Aging commission, the Medicaid 1115 research and demonstration waiver, federal value-based care initiatives, managed care reform and social care integration strategies.

    He served as the Commissioner's Special Advisor where he developed and implemented comprehensive policies and programs aimed at strengthening New York's health systems and payors. His efforts addressed the diverse needs of communities statewide, particularly in the wake of COVID-19, ensuring that all New Yorkers had equitable access to quality healthcare services. Adam's initiatives spanned various demographics, focusing on improving health outcomes and enhancing service delivery for vulnerable populations, including aging individuals, those with disabilities and other underserved communities. He has also implemented initiatives that incentivize healthcare providers to deliver high-value services, particularly for dual-eligible individuals who often face complex healthcare challenges.

    In addition to his regulatory and policy work, Herbst has a strong transactional background, having been involved in numerous mergers and acquisitions within the healthcare sector. He has a proven track record of facilitating partnerships and collaborations that enhance service delivery and operational efficiency. His advocacy for integrated care models fosters collaboration among providers to improve care coordination and patient outcomes. With decades of healthcare regulatory expertise, Herbst is adept at creating alignment strategies for Medicare, Medicaid and other government payer programs.

    "Adam is a nationally recognized leader in the healthcare industry, and we are delighted to welcome him to the firm." said Luca Salvi, chair of Sheppard Mullin. "His multi-dimensional understanding of the marketplace and deep knowledge advising healthcare companies through strategic investments will be invaluable to our clients."

    Eric Klein, leader of the firm's Healthcare industry team added, "The aging population is fueling significant opportunities in the post-acute care sector, including the expansion of existing and creation of new providers, funding and regulation. Adam's reputation and exceptional experience further cements Sheppard Mullin's as the destination for top-tier regulatory and compliance counsel across the aging, hospital care and long-term care sectors."

    "The regulatory landscape for post-acute care providers is complex and ripe for change," added Herbst. "I was drawn to the size and reputation of Sheppard Mullin's nationally known, comprehensive healthcare practice. The attorneys and resources at the firm will allow me to continue providing innovative advice to clients as we navigate the evolving healthcare environment."

    Sheppard Mullin has one of the country's most active long-term care and post-acute care practices, representing all segments of this industry. Recent examples include:

    • Represented private equity firm Clayton, Dubilier & Rice in forming a multibillion-dollar strategic partnership with Elevance Health, Inc. (NYSE:ELV). One of the two largest healthcare services transactions in 2024, the deal launched a new advanced primary care solution that streamlines the patient experience, improves health outcomes and lowers healthcare costs, particularly for the senior population.
    • In one of the largest home health and hospice transactions of the year, Sheppard Mullin is representing leading home-based care service provider, Compassus, in its joint venture with nonprofit health system Providence that will offer home health, hospice and palliative care to patients across Alaska, California, Oregon, Washington and Texas.
    • Advised AccentCare, nationwide post-acute healthcare services leader, in several transactional, regulatory and financing matters, including its acquisition of and joint venture with Memorial Hermann's home health and hospice operations; joint venture with and acquisition of Fairview health system's home health and hospice line of business; home health and hospice joint venture with Baylor Scott & White Health, the largest not-for-profit health system in Texas; and joint ventures with University of California, San Diego and the University of California, Los Angeles.
    • Advised post-acute and specialty home health provider Collage Rehabilitation Partners in its acquisition of Omicron Care, a home health provider to patients with catastrophic injuries including, stroke and neurologic disorders. The acquisition expanded Collage's national continuum of care in new and existing markets.

    Herbst received his B.A., summa cum laude, from American University, his J.D. from Albany Law School, and his M.B.A. from Union College. He is a frequent speaker on healthcare access and technology and currently serves as an adjunct professor at Columbia University's Mailman School of Public Health and at New York Law School, teaching health policy and bioethics.

    About Sheppard Mullin's Healthcare Team

    Sheppard Mullin's 260-attorney national healthcare industry team has been named a Health Care Practice Group of the Year by Law360 three times in seven years. Working in all sectors of healthcare with industry-leading and growing companies, disruptive start-up clients and healthcare-focused investors, Sheppard Mullin is a go-to firm for innovative transactions and joint ventures, regulatory solutions, population health management, global risk and value-based contracting, technology transactions and privacy matters. The team offers significant experience in cybersecurity, tax, non-profit, employment and labor, real estate, artificial intelligence, antitrust, litigation and finance.

    About Sheppard, Mullin, Richter & Hampton LLP

    Sheppard Mullin is a full-service AmLaw 50 firm with more than 1,100 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, industry-leading companies have turned to Sheppard Mullin to handle corporate and technology matters, high-stakes litigation and complex financial transactions. In the U.S., the firm's clients include nearly half of the Fortune 100. For more information, please visit www.sheppardmullin.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241030758975/en/

    Get the next $ELV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • Who has recently joined Sheppard Mullin and what is their area of specialization?

      Adam Herbst has joined Sheppard Mullin as a healthcare partner who specializes in healthcare policy, Medicaid reform, and corporate governance, strengthening the firm's capabilities in the post-acute, aging, and long-term care sectors.

    • What was Adam Herbst's previous role before joining Sheppard Mullin?

      Herbst previously served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care, where he oversaw regulations for various healthcare sectors.

    • What specific focus areas does Adam Herbst emphasize in his work in healthcare policy?

      He focused on transforming healthcare systems to ensure equitable access and improved quality for populations such as children, seniors, and individuals with disabilities.

    • What kind of experience does Adam Herbst bring to Sheppard Mullin in relation to healthcare transactions?

      He has extensive experience in facilitating partnerships and collaborations that enhance service delivery in the healthcare sector, along with a strong transactional background.

    • What distinguishes Sheppard Mullin's healthcare team within the industry?

      Sheppard Mullin has one of the country's most active long-term care and post-acute care practices, which has advised on significant transactions like the partnership between Clayton, Dubilier & Rice and Elevance Health.

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    More analyst ratings

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      7/18/25 1:42:51 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Elevance Health Inc.

      10-Q - Elevance Health, Inc. (0001156039) (Filer)

      7/17/25 3:09:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      7/17/25 6:03:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Elevance Health Inc.

      11-K - Elevance Health, Inc. (0001156039) (Filer)

      6/24/25 2:34:13 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Argus

      Argus downgraded Elevance Health from Buy to Hold

      7/21/25 8:26:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00

      7/18/25 8:10:27 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

      Elevance Health and UC Irvine study underscores potential of digital health tools to reduce asthma burden across U.S. populations A groundbreaking clinical trial led by multidisciplinary researchers found that a digital asthma self-management (DASM) program significantly improved asthma symptom control in adults, with benefits sustained over 12 months. Program participants used everyday devices - like Apple Watch and iPhone – along with a tailored mobile app to help them manage their asthma. The findings represent some of the most compelling evidence to date supporting the use of digital health technologies in asthma care. The virtual, randomized, controlled and decentralized study was

      7/22/25 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Second Quarter 2025 Results

      2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

      7/17/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

      Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

      7/2/25 4:15:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      7/18/25 1:42:51 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

      Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

      3/6/24 4:30:00 PM ET
      $ELV
      $PFMT
      Medical Specialities
      Health Care
      Other Consumer Services
      Consumer Discretionary

    $ELV
    Financials

    Live finance-specific insights

    See more
    • Elevance Health Reports Second Quarter 2025 Results

      2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

      7/17/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

      Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

      7/2/25 4:15:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/24 10:02:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/23 12:37:59 PM ET
      $ELV
      Medical Specialities
      Health Care